PenKid Whitepaper
The current Whitepaper covers practical insights on the AKI diagnostics and highlights the scientific evidence for penKid, a kidney function biomarker.
Click here to…
SphingoTec announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT. Although RRT remains a pivotal measure in treating…
Privacy Policy
1. An overview of data protection
General information
The following information will provide you with an easy to navigate overview of what will happen with your personal data when…
Boditech Med Inc. and SphingoTec GmbH have entered into a non-exclusive royalty-bearing license agreement. Under the terms of this agreement, Boditech has obtained the rights to develop and…
The global burden of sepsis world-wide counts for 49 million cases a year, with a high mortality rate of 11 million deaths. Recent research has identified new molecules that are informative and help…
Bioactive Adrenomedullin (bio-ADM), is a dynamic biomarker for the real time assessment of endothelial function. Loss of endothelial function is causing the formation of edema, shock and subsequent…
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as…
SphingoTec has identified shock and loss of kidney function as major pathways leading to mortality in critical care and we have developed biomarkers diagnosing, predicting, and monitoring these major…
For higher throughput, IVD tests for SphingoTec’s proprietary biomarkers for critical care and preventive medicine are made available as sphingotest® microtiterplate assays.